ACXP
Price
$1.03Alerts
Change
-$0.01 (-0.96%)
Updated
Nov 11 closing price
Capitalization
4.56M
One day until earnings call
Intraday BUY SELL Signals
DYN
Price
$17.99Alerts
Change
+$0.07 (+0.39%)
Updated
Nov 11 closing price
Capitalization
3.37B
113 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ACXP vs DYN

ACXP vs DYN Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ACXP vs. DYN commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACXP is a Hold and DYN is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ACXP with price predictions
Nov 10, 2026

ACXP in upward trend: price may jump up because it broke its lower Bollinger Band on November 05, 2026

ACXP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 43 of 49 cases where ACXP's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ACXP's RSI Oscillator exited the oversold zone, 36 of 47 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 73 cases where ACXP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.

The Moving Average Convergence Divergence (MACD) for ACXP just turned positive on November 09, 2026. Looking at past instances where ACXP's MACD turned positive, the stock continued to rise in 26 of 39 cases over the following month. The odds of a continued upward trend are 67%.

Following a +2.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACXP advanced for three days, in 171 of 227 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACXP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for ACXP entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.559) is normal, around the industry mean (3.498). P/E Ratio (-0.434) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. ACXP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACXP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for DYN with price predictions
Nov 10, 2026

DYN in upward trend: price rose above 50-day moving average on November 06, 2026

DYN moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend. In 25 of 29 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on DYN as a result. In 60 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.

The 10-day moving average for DYN crossed bullishly above the 50-day moving average on November 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 83%.

Following a +7.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where DYN advanced for three days, in 237 of 282 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

DYN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 10-day RSI Indicator for DYN moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 27 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 71%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The 50-day moving average for DYN moved below the 200-day moving average on October 26, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DYN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

The Aroon Indicator for DYN entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.806) is normal, around the industry mean (3.498). P/E Ratio (-5.543) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. DYN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 94 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DYN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
DYN: Fundamental Ratings
DYN
OUTLOOK RATING
1..100
36
VALUATION
overvalued / fair valued / undervalued
1..100
42
Fair valued
PROFIT vs RISK RATING
1..100
94
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
57
P/E GROWTH RATING
1..100
19
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ACXPDYN
RSI
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
71%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
68%
Bearish Trend 2 days ago
88%
Momentum
ODDS (%)
N/A
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bullish Trend 2 days ago
67%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
70%
Bearish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend about 1 month ago
75%
Bullish Trend 3 days ago
84%
Declines
ODDS (%)
Bearish Trend 16 days ago
90%
Bearish Trend 20 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
82%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
78%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (ACXP: $1.04 vs. DYN: $17.92)
Brand notoriety: ACXP and DYN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACXP: 48% vs. DYN: 60%
Market capitalization -- ACXP: $4.56M vs. DYN: $3.37B
ACXP [@Biotechnology] is valued at $4.56M. DYN’s [@Biotechnology] market capitalization is $3.37B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACXP’s FA Score shows that 1 FA rating(s) are green while DYN’s FA Score has 1 green FA rating(s).

  • ACXP’s FA Score: 1 green, 4 red.
  • DYN’s FA Score: 1 green, 4 red.
According to our system of comparison, DYN is a better buy in the long-term than ACXP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACXP’s TA Score shows that 5 TA indicator(s) are bullish while DYN’s TA Score has 5 bullish TA indicator(s).

  • ACXP’s TA Score: 5 bullish, 2 bearish.
  • DYN’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ACXP is a better buy in the short-term than DYN.

Price Growth

ACXP (@Biotechnology) experienced а +1.96% price change this week, while DYN (@Biotechnology) price change was -0.72% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.

Reported Earning Dates

ACXP is expected to report earnings on Nov 12, 2026.

DYN is expected to report earnings on Mar 04, 2027.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

ACXP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACXP has been loosely correlated with KYNB. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ACXP jumps, then KYNB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACXP
1D Price
Change %
ACXP100%
-1.89%
KYNB - ACXP
54%
Loosely correlated
-8.46%
HYPD - ACXP
36%
Loosely correlated
+0.39%
OCGN - ACXP
34%
Loosely correlated
-2.27%
XBIO - ACXP
33%
Poorly correlated
-1.64%
DYN - ACXP
31%
Poorly correlated
-3.76%
More

DYN and

Correlation & Price change

A.I.dvisor indicates that over the last year, DYN has been loosely correlated with RNA. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if DYN jumps, then RNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DYN
1D Price
Change %
DYN100%
-3.76%
RNA - DYN
64%
Loosely correlated
-1.79%
STOK - DYN
53%
Loosely correlated
-1.80%
CLDX - DYN
52%
Loosely correlated
-1.89%
MGTX - DYN
49%
Loosely correlated
+1.37%
SLDB - DYN
49%
Loosely correlated
+2.14%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
DFTT28.090.02
+0.08%
DF Tactical 30 ETF (DFTT)
AELV26.22N/A
N/A
Harbor AlphaEdge Large Cap Value ETF (AELV)
GMAY43.57-0.12
-0.27%
FT Vest U.S. Equity Moderate Buffer ETF - May (GMAY)
JHCB20.29-0.11
-0.54%
John Hancock Corporate Bond ETF (JHCB)
NAC10.25-0.19
-1.82%
Nuveen California Quality Municipal Income Fund